NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022-Reference-Cited by-全球学者库

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Published:2022-09 Issue:9 Volume:20 Page:972-980
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Armstrong Deborah K.¹,Alvarez Ronald D.²,Backes Floor J.³,Bakkum-Gamez Jamie N.⁴,Barroilhet Lisa⁵,Behbakht Kian⁶,Berchuck Andrew⁷,Chen Lee-may⁸,Chitiyo Viola C.⁹,Cristea Mihaela¹⁰,DeRosa Maria¹¹,Eisenhauer Eric L.¹²,Gershenson David M.¹³,Gray Heidi J.¹⁴,Grisham Rachel⁹,Hakam Ardeshir¹⁵,Jain Angela¹⁶,Karam Amer¹⁷,Konecny Gottfried E.¹⁸,Leath III Charles A.¹⁹,Leiserowitz Gary²⁰,Liu Joyce²¹,Martin Lainie²²,Matei Daniela²³,McHale Michael²⁴,McLean Karen²⁵,Miller David S.²⁶,Percac-Lima Sanja¹²,Remmenga Steven W.²⁷,Schorge John²⁸,Stewart Daphne¹⁰,Thaker Premal H.²⁹,Vargas Roberto³⁰,Hendrickson Andrea Wahner⁴,Werner Theresa L.³¹,Zsiros Emese³²,Dwyer Mary A.³³,Hang Lisa³³

Affiliation:

1. 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

2. 2Vanderbilt-Ingram Cancer Center;

3. 3The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

4. 4Mayo Clinic Cancer Center;

5. 5University of Wisconsin Carbone Cancer Center;

6. 6University of Colorado Cancer Center;

7. 7Duke Cancer Institute;

8. 8UCSF Helen Diller Family Comprehensive Cancer Center;

9. 9Memorial Sloan Kettering Cancer Center;

10. 10City of Hope National Medical Center;

11. 11Patient advocate;

12. 12Massachusetts General Hospital Cancer Center;

13. 13The University of Texas MD Anderson Cancer Center;

14. 14University of Washington/Seattle Cancer Care Alliance;

15. 15Moffitt Cancer Center;

16. 16Fox Chase Cancer Center;

17. 17Stanford Cancer Institute;

18. 18UCLA Jonsson Comprehensive Cancer Center;

19. 19O'Neal Comprehensive Cancer Center at UAB;

20. 20UC Davis Comprehensive Cancer Center;

21. 21Dana-Farber/Brigham and Women’s Cancer Center;

22. 22Abramson Cancer Center at the University of Pennsylvania;

23. 23Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

24. 24UC San Diego Moores Cancer Center;

25. 25University of Michigan Rogel Cancer Center;

26. 26UT Southwestern Simmons Comprehensive Cancer Center;

27. 27Fred & Pamela Buffett Cancer Center;

28. 28St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

29. 29Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

30. 30Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

31. 31Huntsman Cancer Institute at the University of Utah;

32. 32Roswell Park Comprehensive Cancer Center; and

33. 33National Comprehensive Cancer Network.

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/9/article-p972.xml

Reference84 articles.

1. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas;Gourley;Int J Gynecol Cancer,2014

2. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas;Gourley;Int J Gynecol Cancer,2014

3. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study;Hurria;J Clin Oncol,2011

4. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes;Gershenson;Gynecol Oncol,2022

5. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial;Pignata;Lancet Oncol,2014

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer;Gynecologic Oncology;2024-05

2. The impact of lymphadenectomy on the survival outcomes of ovarian clear cell carcinoma: A retrospective study of the SEER database and Chinese registry;European Journal of Surgical Oncology;2024-03

3. Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids;Frontiers in Oncology;2024-02-02

4. The -124C>T mutation of TERT promoter indicated a favorable prognosis in OCCC: a monoinstitutional study in China;2024-02-02

5. Apatinib combined with an anti-PD-1 agent promotes antitumour immunity in mice with ovarian cancer;2024-02-02